Open Access

Systemic and renal hemodynamic effects of intra-arterial radiocontrast

  • Paolo Calzavacca1, 2, 3, 4,
  • Ken Ishikawa2, 5,
  • Michael Bailey6,
  • Clive N May2 and
  • Rinaldo Bellomo3, 4Email author
Intensive Care Medicine Experimental20142:32

https://doi.org/10.1186/s40635-014-0032-z

Received: 24 April 2014

Accepted: 12 November 2014

Published: 16 December 2014

Abstract

Background

Decreased renal blood flow (RBF) and vasoconstriction are considered major mechanisms of contrast-induced acute kidney injury (CIAKI). To understand the severity and duration of such putative effects, we measured systemic and renal hemodynamics after intra-arterial radiocontrast administration. The subjects were six Merino ewes. The setting was a university-affiliated research institute. This is a randomized cross-over experimental study.

Methods

Transit-time flow probes were implanted on the pulmonary and left renal arteries 2 weeks before experimentation. We simulated percutaneous coronary intervention by administering five intra-arterial boluses of 0.5 mL/kg saline (control) or radiocontrast (iodixanol) to a total of 2.5 mL/kg over 1 h. Cardiac output (CO), heart rate, mean arterial pressure (MAP), RBF, renal vascular conductance (RVC), urine output (UO), creatinine clearance (CrCl), and fractional excretion of sodium (FENa) were measured.

Results

In the first 8 h after intra-arterial administration of radiocontrast, CO, total peripheral conductance (TPC), and heart rate (HR) increased compared with those after normal saline administration. Thereafter, CO and TPC were similar between the two groups, but HR remained higher with radiocontrast (p < 0.001). After a short (30 min) period of renal vasoconstriction with preserved RBF secondary to an associated increase in MAP, RBF and RVC showed an earlier and greater increase (vasodilatation) with radiocontrast (p < 0.001) and remained higher during the first 2 days. Radiocontrast initially increased urine output (p < 0.001) and FENa (p = 0.003). However, the overall daily urine output decreased in the radiocontrast-treated animals at 2 days (p < 0.001) and 3 days (p = 0.006). Creatinine clearance was not affected.

Conclusions

In healthy animals, intra-arterial radiocontrast increased RBF, induced renal vasodilatation, and caused a delayed period of oliguria. Our findings suggest that sustained reduction in RBF and renal vasoconstriction may not occur in normal large mammals after intra-arterial radiocontrast administration.

Keywords

Radiocontrast agentAngiographyContrast-induced acute kidney injuryRenal vascular resistanceVasoconstrictionRenal blood flowIodixanol

Background

Intra-arterial radiocontrast is used for coronary angiography and/or percutaneous coronary intervention (PCI) worldwide. In at-risk patients, radiocontrast can induce acute kidney injury (AKI). Such contrast-induced acute kidney injury (CIAKI) is one of the leading causes of AKI in hospitals [1]-[7]. CIAKI is independently associated with a higher mortality rate, hospital stay, and cost of care [3].

On the basis of limited experimental studies, two mechanisms have been proposed and are considered important to the development of CIAKI. One is a direct toxic effect of radiocontrast on renal tubular cells with ‘osmotic nephrosis’ [8]-[10], but the pathophysiological relevance of this is unclear because it has only been described ex vivo and it does not logically explain changes in glomerular filtration rate (GFR). The other possible mechanism is a decrease in renal blood flow (RBF) secondary to renal vasoconstriction. Human, dog, and small-animal studies have reported that intravenous infusion of contrast media significantly reduces total renal plasma flow [11]-[14]. However, in these studies, investigators administered amounts of contrast that exceed current practice, measured RBF with techniques of limited accuracy, and performed measurements only for a few hours after radiocontrast administration. The relevance of such findings to a condition which leads to peak GFR losses at 72 h is open to question. We recently used a validated methodology to measure systemic and renal hemodynamics directly, accurately, and over several days by implanted transit-time flow probes [15]-[17] and found that, contrary to expectation, intravenous contrast administration induced only short-lived renal vasoconstriction (first hour) followed by sustained (days) renal vasodilatation and increased RBF [18]. However, such observations may not apply to the most common trigger of CIAKI: intra-arterial boluses of radiocontrast given over a short time during PCI.

Accordingly, we studied the effect of intra-arterial radiocontrast in sheep while continuously measuring renal hemodynamics and repeatedly assessing renal function. We hypothesized that intra-arterial administration might, unlike intravenous administration, induce sustained renal vasoconstriction and, thereby, decrease GFR.

Methods

Animal preparation

We conducted a randomized cross-over study in six adult Merino ewes (weight 33 ± 1 kg). The animals were housed in individual metabolic cages, with free access to food and water. The experimental procedures were approved by the Animal Experimental Ethics Committee of the Florey Institute of Neuroscience under guidelines laid down by the National Health and Medical Research Council of Australia.

The animals underwent three sterile surgical procedures under general anesthesia at intervals of at least 2 weeks. Anesthesia was induced with intravenous sodium thiopentone (10 to 15 mg/kg) for intubation with an endotracheal tube (cuffed size 9). Maintenance of anesthesia was by means of oxygen/air/isoflurane (end-tidal isoflurane 1.5% to 2.0%). Fractional inspired oxygen was altered to maintain SatO2 above 97%, and ventilation was controlled to maintain end-tidal CO2 at approximately 35 mmHg. First, a bilateral carotid arterial loop was created to facilitate subsequent arterial cannulation. During the second procedure, a transit-time flow probe (Transonic Systems, Ithaca, NY, USA) was placed on the pulmonary artery through a left side fourth intercostal space thoracotomy. Finally, during the third procedure, a transit-time flow probe was placed on the left renal artery. The animals were allowed to recover at least 2 weeks from the last surgical procedure before the start of the experiments. In all operations, the animals were treated with intramuscular antibiotics (900 mg, Ilium Propen, procaine penicillin, Troy Laboratories Pty Ltd, Smithfield, NSW, Australia, or Mavlab, Slacks Creek, QLD, Australia) at the start of surgery and then for 2 days post-operatively. Post-surgical analgesia was maintained with intramuscular injection of flunixin meglumine (1 mg/kg) (Troy Laboratories Pty Ltd or Mavlab) at the start of surgery and then 8 and 24 h post-surgery.

The day before the experiment, a Tygon catheter (Cole-Parmer, Boronia, VIC, Australia; ID 1.0 mm, OD 1.5 mm, length 80 cm) was inserted into one carotid arterial loop to measure arterial pressure, to obtain blood samples, and to inject radiocontrast. The insertion of this catheter was performed under fluoroscopic guidance to confirm positioning of the catheter in the ascending aorta. Analog signals (mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), and RBF) were collected on a computer using a customized data acquisition system (LabVIEW, National Instruments, Austin, TX, USA). The data were recorded at 100 Hz for 10 s every minute during experiments. Standard formulae were applied to calculate total peripheral conductance (TPC = CO/MAP) and renal vascular conductance (RVC = RBF/MAP).

Urine output (UO) was collected hourly through an automated urine fraction collector at hourly intervals for 5 days (2 days baseline, day 0, and 2 days post-intervention). Two-hour creatinine clearance (CrCl) and fractional excretion of sodium (FENa) were calculated according to standard formulae: CrCl = (UCreat × UO)/(PCreat/time(min)), where UCreat is urine creatinine, PCreat plasma creatinine, and UO urine volume in 2 h; FENa = PNa/UNa × CrCl × 100, where PNa is plasma concentration and UNa urine concentration of sodium.

Experimental protocol

Baseline hemodynamic and UO measurements were collected for 48 h prior to the administration of control fluid (normal saline) or the radiocontrast agent (iodixanol, Visipaque™, GE Healthcare, Milwaukee, WI, USA). To replicate a coronary angiogram study (PCI), we observed several PCIs at our institution and replicated practice in our model. Thus, normal saline or iodixanol was infused intra-arterially as five boluses of 0.5 mL/kg at 12-min intervals. Blood samples were taken before the start and then at 2, 4, 8, 24, 48, and 72 h after the injections. Urine was collected hourly throughout the experiment from the bladder catheter and sampled in 2-h lots at the predefined time points for creatinine clearance and fractional excretion of urea measurements up to the third day after the administration of control or radiocontrast. Bladder catheters were then removed. The hemodynamic parameters were followed for a total of 5 days after saline or radiocontrast administration. The animals had free access to food and water with food given at 5 p.m. every day. However, the day of the injection, fluid and water were restricted from 8 a.m. to 4 p.m. to avoid confounders on urine output and hemodynamic variables. Daily water intake was also recorded for every animal.

Statistical analysis

All data are presented as means ± standard error of means (SEM) or geometric means (95% confidence interval) as appropriate. For baseline values, averages of the 48 h of baseline are presented. Hour-by-hour values for the first 8 h and daily averages up to the fifth day were compared with the average of baseline values by analysis of variance. To adjust for multiple comparisons, p < 0.01 was used to indicate significance. Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). All variables were assessed for normality and log-transformed where appropriate.

Mixed linear modeling was performed with each sheep treated as a random effect. Main effects were fitted for time and treatment with an interaction between time and treatment used to determine if treatments behaved differently over time. Specific time point comparisons were performed using post hoc pairwise t-tests. To account for multiple comparisons, a reduced p value of 0.01 was considered to be statistically significant.

Results

Systemic hemodynamics

In the first 8 h, intra-arterial administration of radiocontrast increased CO, TPC, and HR more than that of normal saline (Table 1 and Figure 1) without any difference in MAP. Daily changes in CO and TPC were not different between the two groups (p = 0.10 and p = 0.30, respectively, for CO and TPC) (Table 2 and Figure 2). MAP was higher at baseline in the radiocontrast-treated animals and remained higher with radiocontrast during the following 5 days, with significant differences (p < 0.001) between groups (Table 2). HR was also higher with radiocontrast (Table 2). The differences between the groups, although statistically significant, were small and occurred with full preservation of the normal circadian rhythm (Figure 2).
Table 1

Haemodynamic values at baseline and during the first 8 hours after arterial radiocontrast

 

GROUP

Baseline

1sthour

2ndhour

3rdhour

4thhour

5thhour

6thhour

7thhour

8thhour

CO (L/min)

Saline

3.52 (±0.26)*

3.70 (±0.27)°

3.65 (±0.27)

3.46 (±0.27)*

3.35 (±0.27)°

3.36 (±0.27)°

3.23 (±0.27)°

3.12 (±0.27)°

3.35 (±0.27)°

Contrast

3.25 (±0.26)*

3.66 (±0.27)°

3.80 (±0.27)°

3.31 (±0.27)*

3.30 (±0.27)

3.53 (±0.27)°

3.37 (±0.27)

3.32 (±0.27)

3.47 (±0.27)°

HR (bpm)

Saline

65 (±4)

66 (±5)*

65 (±5)*

64 (±5)

60 (±5)°*

60 (±5)°*

58 (±5)°*

56 (±5)°*

60 (±5)°*

Contrast

64 (±4)

76 (±5)°*

86 (±5)°*

68 (±5)

67 (±5)*

72 (±5)°*

68 (±5)*

65 (±5)*

69 (±5)°*

MAP (mmHg)

Saline

88 (±2)*

87 (±2)

88 (±2)

85 (±2)°

87 (±2)

86 (±2)

87 (±2)

85 (±2)°

86 (±2)

Contrast

95 (±2)*

95 (±2)

95 (±2)

92 (±2)°

91 (±2)°

94 (±2)

93 (±2)

92 (±2)°

93 (±2)

TPC (mL/min/mmHg)

Saline

39.8 (±3.0)*

42.2 (±3.0)°*

41.0 (±3.0)

40.4 (±3.0)*

38.3 (±3.0)

38.9 (±3.0)

37.1 (±3.0)°

36.3 (±3.0)°

38.8 (±3.0)

Contrast

35.0 (±3.0)*

39.9 (±3.0)°*

40.3 (±3.0)°

36.3 (±3.0)*

36.7 (±3.0)°

38.4 (±3.0)°

36.5 (±3.0)

36.3 (±3.0)

37.9 (±3.0)°

RBF (mL/min)

Saline

167 (±19)*

171 (±19)*

176 (±19)°

181 (±19)°*

177 (±19)°*

170 (±19)*

166 (±19)*

165 (±19)*

166 (±19)*

Contrast

156 (±19)*

157 (±19)*

183 (±19)°

189 (±19)°*

191 (±19)°*

195 (±19)°*

191 (±19)°*

190 (±19)°*

188 (±19)°*

RVC (mL/min/mmHg)

Saline

1.83 (±0.19)*

1.96 (±0.19)°*

1.96 (±0.19)°

2.11 (±0.19)°

2.00 (±0.19)°*

1.96 (±0.19)°*

1.90 (±0.19)°*

1.92 (±0.19)°*

1.93 (±0.19)°*

Contrast

1.66 (±0.19)*

1.68 (±0.19)*

1.95 (±0.19)°

2.05 (±0.19)°

2.10 (±0.19)°*

2.12 (±0.19)°*

2.09 (±0.19)°*

2.06 (±0.19)°*

2.04 (±0.19)°*

UO (mL/h)

Saline

12 (±8)

30 (±10)*

27 (±10)*

27 (±10)

23 (±10)

25 (±10)

21 (±10)

24 (±10)

25 (±10)

Contrast

17 (±8)

66 (±10)°*

70 (±10)°*

30 (±10)

30 (±10)

16 (±10)

17 (±10)

10 (±10)

15 (±10)

°: p≤0.01 for within group time comparison with baseline; *: p≤0.01 for between-group comparison. Note: UO baseline: average of last 2 hours of baseline monitoring.

Figure 1

Hemodynamic changes in the first 8 h after radiocontrast administration. Changes in systemic and renal hemodynamics from baseline after an intra-arterial bolus of radiocontrast agent or saline. Values are mean ± SEM at 5-min intervals.

Table 2

Haemodynamic values during the first 5 days after radio-contrast injection

 

GROUP

Baseline

1stday

2ndday

3rdday

4thday

5thday

CO (L/min)

Saline

3.52 (±0.26)*

3.52 (0.30)

3.41 (0.30)°*

3.29 (0.30)°

3.40 (0.30)°

3.46 (0.30)*

Contrast

3.25 (±0.26)*

3.42 (0.30)°

3.24 (0.30)*

3.18 (0.30)

3.31 (0.30)

3.21 (0.30)*

HR (bpm)

Saline

65 (±4)

64 (±4)*

61 (±4)°*

60 (±4)°*

62 (±4)°*

63 (±4)

Contrast

64 (±4)

69(±4)°*

65 (±4)*

64 (±4)*

67 (±4)*

65 (±4)

MAP (mmHg)

Saline

88 (±2)*

87 (±1)*

85 (±1)°*

86 (±1)*

84 (±1)°*

86 (±1)*

Contrast

95 (±2)*

93 (±1)°*

92 (±1)°*

91 (±1)°*

89 (±1)°*

89 (±1)°*

TPC (mL/min/mmHg)

Saline

39.8 (±3.0)*

40.5 (±3.6)*

39.9 (±3.6)*

38.1 (±3.6)°*

40.6 (±3.6)*

40.2 (±3.6)*

Contrast

35.0 (±3.0)*

37.5 (±3.6)°*

35.6 (±3.6)*

35.3 (±3.6)*

37.8 (±3.6)°*

36.9 (±3.6)°*

RBF (mL/min)

Saline

167 (±19)*

171 (±18)*

166 (±18)

163 (±18)*

166 (±18)*

174 (±18)*

Contrast

156 (±19)*

181 (±18)°*

163 (±18)°

153 (±18)*

155 (±18)*

150 (±18)*

RVC (mL/min/mmHg)

Saline

1.83 (±0.19)*

1.93 (±0.18)°

1.94 (±0.18)°*

1.88 (±0.18)°*

1.97 (±0.18)°*

2.00 (±0.18)°*

Contrast

1.66 (±0.19)*

1.97 (±0.18)°

1.78 (±0.18)°*

1.69 (±0.18)°*

1.75 (±0.18)*

1.72 (±0.18)°*

UO (mL/h)

Saline

20 (±3)

24 (±3)

18 (±3)

16 (±3)

  

Contrast

20 (±3)

22 (±3)

14 (±3)°

16 (±3)°

  

Daily UO (mL/24 hours)

Saline

380 (262;650)*

535 (341;813)

441 (344;532)*

386 (276;512)

  

Contrast

543 (162;924)*

529 (534;295)

349 (257;427)*

329 (196;596)*

  

°: p≤0.01 for within group time comparison with baseline; *: p≤0.01 for between-group comparison.

UO: urinary output during that hour; daily UO: average of urinary output over24 hours. Bladder catheter removed after day 3.

Figure 2

Changes in systemic hemodynamics over a 5-day period of observation. Changes in systemic and renal hemodynamics from baseline after an intra-arterial bolus of radiocontrast agent or saline. Values are mean ± SEM at hourly intervals.

Renal hemodynamics

After a short (30 min) period of renal vasoconstriction with preserved RBF secondary to an associated increase in MAP (Figure 1), in the first 8 h (Table 1 and Figure 1), RBF and RVC showed an earlier and greater increase in the radiocontrast-treated animals (p < 0.001) and both RBF and RVC remained higher during the following 2 days (Table 2 and Figure 3). By day 3, RBF and RVC had returned to baseline values. The circadian rhythms of RBF and RVC were preserved.
Figure 3

Changes in renal hemodynamics over a 5-day period of observation. Changes in systemic and renal hemodynamics from baseline after an intra-arterial bolus of radiocontrast agent or saline. Values are mean ± SEM at hourly intervals.

Renal function

Radiocontrast increased urine output at the first and the second hour (both p < 0.001 compared to baseline) (Figure 3) and FENa at 2 h (p = 0.003 for comparison with baseline) (Figure 4). Normal saline did not affect urine output, creatinine clearance, or fractional excretion of sodium. Creatinine clearance was not changed at any time point by radiocontrast administration; however, the overall daily urine output decreased in the radiocontrast-treated animals after 2 days (p < 0.001) and 3 days (p = 0.006) (Table 2).
Figure 4

Renal functional changes after radiocontrast administration. (a) Creatinine clearance and (b) fractional excretion of sodium after an intra-arterial bolus of radiocontrast agent or saline. Values are mean ± SEM. Asterisk indicates p ≤ 0.01 for between-group comparison.

Discussion

Key findings

We performed an experimental study in conscious large animals to assess the systemic and renal hemodynamic effects of repeated intra-arterial boluses of radiocontrast, simulating PCI-associated contrast administration. Measurements were taken over 5 days following administration of contrast, the period when CIAKI typically becomes clinically manifest. Intra-arterial radiocontrast induced an early and short-lived (hours) increase in heart rate and cardiac output with peripheral vasodilatation. Contrary to our hypothesis, we found that radiocontrast caused a large increase in renal blood flow and renal vasodilatation in the first 8 h, which returned to control over 48 h. Functionally, radiocontrast did not affect creatinine clearance, but caused an early (first 2 h) increase in urine output and FENa followed by a delayed decrease in urine output by days 2 and 3.

Relationship to previous studies

Our experimental findings are unique because of the detailed and prolonged measurement of RBF with highly accurate technology. No such extended studies of the systemic and renal hemodynamic effects of intra-arterial radiocontrast administration have been performed. Our findings are at odds with some previous studies which demonstrate vasoconstriction after contrast medium administration [11]-[14]. They are, however, in concordance with other work by our group, which found that intravenous radiocontrast induced a quantitatively dominant and prolonged renal vasodilatation lasting at least 72 h after treatment. They are also in concordance with the only other study that performed some limited extended monitoring of RBF after radiocontrast administration [19].

If radiocontrast injection also induced vasodilatation and global hyperemia in man, it might seem counterintuitive that decreased GFR and oliguria would follow, as seen with CIAKI in at-risk patients. However, glomerular capillary filtration pressure is dependent on the relationship between afferent and efferent arteriolar tone. If, for example, afferent vasodilatation was associated with greater efferent vasodilatation (as might be the case with angiotensin-converting enzyme inhibitors), then an increase in renal blood flow (hyperemia) would occur together with a decrease in intraglomerular capillary pressure, oliguria (as seen in our animals), and a decrease in GFR (not seen in our healthy animals or in previously healthy patients). This mechanism may be responsible for the decreased GFR of radiocontrast exposure. Studies using selective efferent arteriolar vasoconstrictors may help clarify the role of this mechanism in the pathogenesis of the observed vasodilatation.

Implications of study findings

Our findings do not support the view that the functional changes induced by intra-arterial radiocontrast administration are explained by reduced RBF and/or renal vasoconstriction as is currently reported and published [20]. They imply that efforts to prevent CIAKI by administering agents known to induce vasodilatation (low-dose dopamine and/or fenoldopam) are unlikely to be successful and that vasopressor agents that preferentially increase resistance in the efferent arteriole [19],[20] may be more logical.

Strengths and limitations

Our study has several strengths. First, we measured RBF and renal vascular conductance continuously with highly accurate technology, every minute for an extended period of observation. Second, we created a model which simulated the observed practice of intra-arterial radiocontrast administration as delivered in the cardiac catheterization laboratory of a tertiary invasive cardiology unit, making our findings highly relevant at a clinical level. Third, we combined systemic and renal hemodynamics with some measures of renal function.

However, our experimental study also has several limitations. We studied a specific radiocontrast agent and our findings may not apply to different agents. We studied a specific species which may not be representative of effects in other animals, including man. We used normal animals and our model did not induce a decrease in GFR. Thus, it is uncertain how these findings may apply in the setting of contrast-induced nephropathy or in humans where age and comorbidities profoundly influence renal functional outcomes. We were unable to assess tubular injury, which may be an important mechanism leading to subsequent loss of GFR. We did not measure GFR with sophisticated and sensitive techniques. Thus, changes in GFR may have occurred and have been missed. However, the clinical significance of such changes (if present) would remain unclear. We did not measure biomarkers of tubular injury [21], but our research focus was on the systemic and renal hemodynamic effects of radiocontrast and the relevance of such biomarkers remains unclear [22],[23]. We did not obtain biopsies to ascertain the degree of apoptosis or histological injury. However, in order to conduct the experiments to 5 days, we were not able to perform post-mortem studies and did not want to affect hemodynamic measurements by any damage that biopsy might have induced. Moreover, our measurements apply to global renal blood flow and do not provide information on changes in the renal microvasculature which might have diverted blood to either the cortex or the medulla and caused medullary hypoxia as shown in animal models by blood oxygen level-dependent (BOLD) MRI-based techniques [24]-[26]. We also acknowledge that there is substantial evidence that contrast agents decrease medullary perfusion and oxygenation. For instance, BOLD MRI studies showed declining medullary oxygenation in healthy individuals [27]; contrast media lead to pimonidazole immunostaining and stabilize medullary HIF to a moderate extent, even without COX or NOS inactivation [28], particularly in the presence of predisposing factors, such as diabetes [29]. Furthermore, at least one study found tubuloglomerular feedback (TGF) activation when contrast media were flushed through the medullary thick ascending loop of Henle/macula densa [30], providing evidence for a tubular process causing loss of GFR. Our study does not address any of these possible mechanisms of injury. Finally, data such as tissue hypoxia [31], declining medullary flows [32], or urine NGAL release [33] suggest that renal medullary hypoperfusion and parenchymal injury conceivably take place at the very early period after the injection of radiocontrast. It remains uncertain, however, whether such a large body of observed pathophysiological events truly contributes to AKI or represents a constellation of epiphenomena.

Conclusions

In an experimental study extended over 5 days, we found that intra-arterial radiocontrast increased renal blood flow and induced renal vasodilatation. This effect was marked in the first 8 h and persisted for approximately 48 h. Our findings suggest that sustained reduction in RBF and renal vasoconstriction may not occur in normal large mammals after intra-arterial radiocontrast administration.

Declarations

Authors’ Affiliations

(1)
Department of Anaesthesia and Intensive Care, Uboldo Hospital
(2)
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne
(3)
Department of Intensive Care and Department of Medicine, Austin Hospital and The University of Melbourne
(4)
Department of Pediatrics, Iwate Medical University
(5)
Australian and New Zealand Intensive Care Research Centre, Monash University
(6)
Australian and New Zealand Intensive Care Research Centre, Monash University

References

  1. Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D, O'Dea F, Stone E, Reddy R, McManamon PJ: Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992, 41: 1274–1279. 10.1038/ki.1992.189PubMedView ArticleGoogle Scholar
  2. Briguori C, Tavano D, Colombo A: Contrast agent–associated nephrotoxicity. Prog Cardiovasc Dis 2003, 45: 493–503. 10.1053/pcad.2003.YPCAD16PubMedView ArticleGoogle Scholar
  3. McCullough PA, Soman SS: Contrast-induced nephropathy. Crit Care Clin 2005, 21: 261–280. 10.1016/j.ccc.2004.12.003PubMedView ArticleGoogle Scholar
  4. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995, 47: 254–261. 10.1038/ki.1995.32PubMedView ArticleGoogle Scholar
  5. Solomon R: Contrast-medium-induced acute renal failure. Kidney Int 1998, 53: 230–242. 10.1038/sj.ki.4495510PubMedView ArticleGoogle Scholar
  6. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994, 331: 1416–1420. 10.1056/NEJM199411243312104PubMedView ArticleGoogle Scholar
  7. Taliercio CP, Vlietstra RE, Ilstrup DM, Burnett JC, Menke KK, Stensrud SL, Holmes DR Jr: A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991, 17: 384–390. 10.1016/S0735-1097(10)80103-2PubMedView ArticleGoogle Scholar
  8. Haller C, Hizoh I: The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol 2004, 39: 149–154. 10.1097/01.rli.0000113776.87762.49PubMedView ArticleGoogle Scholar
  9. Hizoh I, Haller C: Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol 2002, 37: 428–434. 10.1097/00004424-200208000-00003PubMedView ArticleGoogle Scholar
  10. Moreau JF, Droz D, Noel LH, Leibowitch J, Jungers P, Michel JR: Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol 1980, 15: S54-S60. 10.1097/00004424-198011001-00014PubMedView ArticleGoogle Scholar
  11. Deray G, Bagnis C, Jacquiaud C, Dubois M, Adabra Y, Jaudon C: Renal effects of low and isoosmolar contrast media on renal hemodynamic in a normal and ischemic dog kidney. Invest Radiol 1999, 34: 1–4. 10.1097/00004424-199901000-00001PubMedView ArticleGoogle Scholar
  12. Hetzel GR, May P, Hollenbeck M, Voiculescu A, Modder U, Grabensee B: Assessment of radiocontrast media induced renal vasoconstriction by color coded duplex sonography. Ren Fail 2001, 23: 77–83. 10.1081/JDI-100001286PubMedView ArticleGoogle Scholar
  13. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L: Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995, 6: 1451–1458.PubMedGoogle Scholar
  14. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002, 143: 894–903. 10.1067/mhj.2002.122118PubMedView ArticleGoogle Scholar
  15. Langenberg C, Wan L, Bagshaw SM, Egi M, May CN, Bellomo R: Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant 2006, 21: 3389–3397. 10.1093/ndt/gfl541PubMedView ArticleGoogle Scholar
  16. Langenberg C, Wan L, Egi M, May CN, Bellomo R: Renal blood flow in experimental septic acute renal failure. Kidney Int 2006, 69: 1996–2002. 10.1038/sj.ki.5000440PubMedView ArticleGoogle Scholar
  17. Langenberg C, Wan L, Egi M, May CN, Bellomo R: Renal blood flow and function during recovery from experimental septic acute kidney injury. Intensive Care Med 2007, 33: 1614–1618. 10.1007/s00134-007-0734-8PubMedView ArticleGoogle Scholar
  18. Saotome T, Langenberg C, Wan L, Ramchandra R, May CN, Bellomo R, Bailey M, Bagshaw SM: Early and sustained systemic and renal hemodynamic effects of intravenous radiocontrast. Blood Purif 2010, 29: 339–346. 10.1159/000302721PubMedView ArticleGoogle Scholar
  19. Wan L, Langenberg C, Bellomo R, May CN (2009) Angiotensin II in experimental hyperdynamic sepsis. Crit Care 13:R190Google Scholar
  20. Edwards RM, Trizna W, Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989, 256: F274-F278.PubMedGoogle Scholar
  21. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365: 1231–1238. 10.1016/S0140-6736(05)74811-XPubMedView ArticleGoogle Scholar
  22. Martensson J, Martling CR, Bell M: Novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesth 2012, 109: 843–850. 10.1093/bja/aes357PubMedView ArticleGoogle Scholar
  23. Martensson J, Xu S, Bell M, Martling CR, Venge P: Immunoassays distinguishing between HNL/NGAL released in urine from kidney epithelial cells and neutrophils. Clin Chim Acta 2012, 413: 1661–1667. 10.1016/j.cca.2012.05.010PubMedView ArticleGoogle Scholar
  24. Prasad PV, Priatna A, Spokes K, Epstein FH: Changes in intrarenal oxygenation as evaluated by BOLD MRI in a rat kidney model for radiocontrast nephropathy. J Magn Reson Imaging 2001, 13: 744–747. 10.1002/jmri.1103PubMedPubMed CentralView ArticleGoogle Scholar
  25. Haneder S, Aufgustin J, Jost G, Pietsch H, Lengsfeld P, Krämer BK, Schoenberg SO, Meyer M, Attenberger UI, Michaely HJ: Impact of iso- and low-osmolar iodinated contrast agents on BOLD and diffusion MRI in swine kidneys. Invest Radiol 2012, 47: 299–305. 10.1097/RLI.0b013e318240a8acPubMedView ArticleGoogle Scholar
  26. Li P, Thacker J, Lu J, Franklin T, Zhou Y, Papadopoulou MV, Solomon R, Prasad PV: Efficacy of preventive interventions for iodinated contrast-induced acute kidney injury evaluated by intrarenal oxygenation as an early marker. Invest Radiol 2014, 49: 647–652. 10.1097/RLI.0000000000000065PubMedPubMed CentralView ArticleGoogle Scholar
  27. Hofmann L, Simon-Zoula S, Nowak A, Giger A, Vock P, Boesch C, Frey FJ, Vogt B: BOLD-MRI for the assessment of renal oxygenation in humans: acute effect of nephrotoxic xenobiotics. Kidney Int 2006, 70: 144–150. 10.1038/sj.ki.5000418PubMedView ArticleGoogle Scholar
  28. Rosenberger C, Rosen S, Shina A, Bernhardt W, Wiesener MS, Frei U, Eckardt KU, Heyman S: Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int 2006, 70: 60–70. 10.1038/sj.ki.5000395PubMedView ArticleGoogle Scholar
  29. Khamaisi M, Raz I, Shile V, Shina A, Rosenberger C, Dahan R, Abassi Z, Meidan R, Lecht S, Heyman SN: Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney Int 2008, 74: 91–100. 10.1038/ki.2008.112PubMedView ArticleGoogle Scholar
  30. Liu ZZ, Schmerbach K, Lu Y, Perlewitz A, Nikitina T, Cantow K, Seeliger E, Persson PB, Patzak A, Liu R, Sendeski MM: Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback. Am J Physiol Renal Physiol 2014, 306: F864-F872. 10.1152/ajprenal.00302.2013PubMedPubMed CentralView ArticleGoogle Scholar
  31. Liss P, Nygren A, Erikson U, Ulfendahl HR: Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 1998, 53: 698–702. 10.1046/j.1523-1755.1998.00811.xPubMedView ArticleGoogle Scholar
  32. Liss P, Nygrean A, Olsson U, Ulfendahl HR, Erikson U: Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int 1996, 49: 1268–1275. 10.1038/ki.1996.181PubMedView ArticleGoogle Scholar
  33. Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH 3rd, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P: NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007, 22: 2089–2095. 10.1007/s00467-007-0601-4PubMedView ArticleGoogle Scholar

Copyright

© Calzavacca et al.; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.